Treatment(s) now being considered-Hormonal therapy Page 2 Posts on Medivizor
Navigation Menu

Treatment(s) now being considered-Hormonal therapy Posts on Medivizor

Can the neutrophil to lymphocyte ratio predict outcome in enzalutamide-treated prostate cancer patients?

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to determine whether the neutrophil to lymphocyte ratio (NLR) can be used to determine outcome in CRPC patients treated with enzalutamide (Xtandi). It was concluded that NLR could be used to predict the outcome for CRPC patients treated with enzalutamide.  Some background Treatment for metastatic...

Read More

Can radiation therapy and antiandrogen therapy improve survival in recurrent prostate cancer?

Posted by on Feb 20, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study was to examine whether combining radiation therapy and antiandrogen therapy improved survival in patients with prostate cancer that is not cured by initial treatment. It was concluded that the combination of radiation therapy and antiandrogen therapy improved survival when compared to radiation therapy...

Read More

Extended adjuvant therapy in hormone-receptor-positive early breast cancer

Posted by on Jan 21, 2017 in Breast cancer | 0 comments

In a nutshell This review examined the benefits of extending hormone therapy from 5 to 10 years in patients with hormone receptor positive breast cancer. The study concluded that treatment recommendations should take factors such as previous treatments and potential side effects into account. Some background Hormone-receptor (HR)-positive breast...

Read More

Comparing outcomes of radiation therapy and observation in patients over 80

Posted by on Jan 5, 2017 in Prostate cancer | 0 comments

In a nutshell This study examined different treatment options for elderly men with localized prostate cancer. Researchers reported that radiation therapy with or without hormone therapy was associated with a significant survival benefit when compared to observation alone. Some background Localized prostate cancer refers to cancer that is confined...

Read More

Hormone therapy during or after radiation therapy increases the risk of cardiovascular events

Posted by on Dec 12, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effect of androgen deprivation therapy (ADT) on the risk of cardiovascular events (such as stroke or heart attack) in men treated with radiation therapy. Researchers concluded that ADT use during or after radiation therapy increases the risk of cardiovascular events. Some background Radiation therapy is a...

Read More

Should immunotherapy be administered before or after hormone therapy?

Posted by on Dec 12, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether immunotherapy with sipuleucel-T (Provenge) shows a greater immune response if administered before or after androgen deprivation therapy (ADT). Authors present preliminary evidence of improved immune cell response when sipuleucel-T was administered first in patients with recurrent prostate cancer at high risk of...

Read More

Early use of chemotherapy in metastatic prostate cancer – an overview of current evidence

Posted by on Nov 27, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined evidence for the benefits of adding chemotherapy early to hormone therapy for metastatic prostate cancer. Authors concluded that early evidence indicates a survival benefit with the addition of chemotherapy for metastatic prostate cancer. Some background Androgen deprivation therapy (ADT) is a type of hormone...

Read More

Hormone therapy may shorten survival in African American men with low- or intermediate-risk prostate cancer

Posted by on Aug 13, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effect of ethnicity on health outcomes with androgen deprivation therapy (ADT). Researchers reported shorter survival among African American men receiving ADT for low- or intermediate-risk prostate cancer compared to men of other ethnicities. Some background ADT is a type of hormone therapy used to treat...

Read More

Does hormone therapy increase the risk of falls?

Posted by on Aug 13, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the relationship between androgen deprivation therapy (ADT) and the risk of falls. Authors present preliminary evidence suggesting that patients receiving ADT may be at increased risk of falls. Some background ADT is a type of hormone therapy commonly used to treat advanced prostate cancer. By reducing the levels...

Read More

The effect of combined radiation and hormone therapy on long-term fatigue

Posted by on Jul 18, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined the effect of combined radiation and hormone therapy on long-term fatigue. Researchers reported severe fatigue during and up to 4 years after treatment. Men with increased cancer markers and symptoms were more likely to report higher fatigue levels. Some background Radiation therapy and hormone therapy are often...

Read More